CAS: 69304-47-8; 5-((E)-2-Bromovinyl)-1-((2R,4S,5R)-4-Hydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)Pyrimidine-2,4(1H,3H)-Dione

该化合物是一种抗病毒药物,主要用于治疗流行为shingles的雌性疹,是一种核素类比,具体抑制病毒性DNA合成,从而阻止了菌-zoster病毒的复制;布里武丁的化学结构特征是其经修改的核素表面框架,这增强了其针对病毒的选择性和有效性;它通常以口服方式进行,以其有利的药理基因特征而著称,允许每天一次服用. 布里武丁一般是很好的,尽管它可能会造成副作用,如胃肠紊乱或某些病人的皮肤反应. 重要的是,它不应与某些其他抗病毒药物,如兹维多丁,一起使用,因为它可能增加毒性. 总的来说,布里武丁是抗病毒疗法的一个重大进步,特别是对于患菌的人来说,它是一种有效的选择,可以管理这一痛苦状况.

结构式图片

上下游产品

-2'-deoxyuridine3',5'-Di-O-acetyl-(Z)-5-2-(trimethylsilyl)ethenyl-2'-deoxyuridine 5-(1-fluoro-2-bromoethyl)-3',5'-di-O-acetyl-2'-deoxyuridine (E)-5-(2-bromovinyl)-2'-deoxy-3',5'-di-O-(p-toluoyl)uridine (E)-3-(1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acrylic acid(E)-5-(2-bromovinyl)-1-(2-deoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one 3',5'-di-O-acetyl-(E)-5-(2-bromovinyl)-2'-deoxyuridine (E)-5-(2-bromovinyl)-2'-deoxy-5'-O-p-toluenesulphonyluridine (E)-5-(2-bromovinyl)-2'-deoxy-5'-O-t-butyldiphenylsilyluridine

合成工艺路线路线简述

    1-(3,5-Di-O-Acetyl-2-Deoxy-β-D-Erythro-Pentofuranosyl)-5-(Trimethylsilylethynyl)Uracil置于lindlar'S Catalyst 喹啉,甲醇,氨,氢气,溴体系中,用 乙酸乙酯 作为反应溶剂,-100.0~25.0 °C,101.33 Kpa 条件下,反应 23.58H,反应生成 溴夫定
    参考文献:Nucleic Acid Related Compounds. 39. Efficient Conversion Of 5-Iodo To 5-Alkynyl And Derived 5-Substituted Uracil Bases And Nucleosides
    标题:Nucleic Acid Related Compounds. 39. Efficient Conversion Of 5-Iodo To 5-Alkynyl And Derived 5-Substituted Uracil Bases And Nucleosides
    摘要:
    DOI:10.1021/jo00159A012

    海关参考信息

    专利信息


    专利号:US-11858953-B2
    优先权日:2018-04-04
    标 题:Compositions and methods for synthesis of phosphorylated molecules
    发明人:CHAPUT JOHN; LIAO JEN-YU; BALA SAIKAT
    权利人:UNIV CALIFORNIA
    摘要:The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

    专利号:US-6818633-B2
    优先权日:2001-06-29
    标题:Antiviral compounds and methods for synthesis and therapy
    发明人:BALZARINI JAN M R; DE CLERCQ ERIK D A; HOLY ANTONIN
    权利人:ACAD OF SCIENCE CZECH REPUBLIC; REGA STICHTING
    摘要:Novel compounds are provided having formula (I)whereR1, R2, R3, R4, Z, X and * are defined herein. Also provided are antiviral methods for use and processes for synthesis of the compounds of formula (I).

    专利号:US-11649285-B2
    优先权日:2016-08-03
    标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
    发明人:KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
    权利人:BIO TECHNE CORP
    摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

    专利号:US-10370455-B2
    优先权日:2014-12-05
    标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
    发明人:MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
    权利人:IMMUNEXT INC
    摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

    专利号:US-7115592-B2
    优先权日:2003-06-16
    标题:Phosphonate substituted pyrimidine compounds and methods for therapy
    发明人:BALZARINI JAN M R; DE CLERCQ ERIK D A; HOLY ANTONIN; HOCKOVA DANA
    权利人:BIOCHEMISTRY OF THE ACADEMY OF
    摘要:Novel compounds are provided having formula (I) n nwheren n R 1 , R 2 , R 3 , R 4 , Z, X and * are defined herein. Also provided are antiviral methods for use and processes for synthesis of the compounds of formula (I).

    专利号:US-2008051323-A1
    优先权日:2004-08-21
    标 题 :Chloroquine drug compositions and methods for their synthesis
    发明人:KOSAK KENNETH M
    权利人:KOSAK KENNETH M
    摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. n The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.
    上海泽涵生物医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zehanbiopharma.com
    电话: 021-61350663 13052117465👤
    📞上海泽涵生物医药科技有限公司 ⚠️参考联系方式

    销售电话:021-61350663 13052117465
    邮箱:sales@zehanbiopharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海祥耕科技发展有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.sharingtechcn.com
    电话: 0086 (21) 6049-5188👤
    📞上海祥耕科技发展有限公司 ⚠️参考联系方式

    销售电话:0086 (21) 6049-5188
    邮箱:sharing@sharingtechcn.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: 10.3390/v14020192.
    2: Rabasseda X. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc). 2003 May;39(5):359-71. doi: 10.1358/dot.2003.39.5.740221. 26(4):1132. doi: 10.3390/molecules26041132.
    4: Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJ, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl

    合成参考文献


    摘要:Chemioterapia Antimicrobica., 4(70), 1981
    摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from
    参考文献:10.1021/jm991017z
    摘要:Raić-Malić S, Hergold-Brundić A, Nagl A, Grdisa M, Pavelić K, De Clercq E, Mintas M. Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. J Med Chem. 1999 Jul 15;42(14):2673–8. doi: 10.1021/jm991017z.
    参考文献:10.1007/s00268-002-4053-5
    摘要:Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg. 2002 Jul;26(7):783–9. doi: 10.1007/s00268-002-4053-5.
    参考文献:10.1007/s00063-002-1135-y
    摘要:Sauerbrei A, Sommer M, Eichhorn U, Wutzler P. [Laboratory diagnosis of herpes zoster: virology or serology ]. Med Klin (Munich). 2002 Mar 15;97(3):123–7. doi: 10.1007/s00063-002-1135-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知